PD - L1 （SP263）表达与前列腺癌病理侵袭参数相关

IF 1.5 4区医学 Q3 PATHOLOGY

Annals of Diagnostic Pathology Pub Date : 2025-04-12 DOI:10.1016/j.anndiagpath.2025.152481

Xiaopeng Zhuang , Huiting Li , Zhijie You , Hui Cheng , Guodong Guo , Xin Chen , Haijian Huang

{"title":"PD - L1 （SP263）表达与前列腺癌病理侵袭参数相关","authors":"Xiaopeng Zhuang , Huiting Li , Zhijie You , Hui Cheng , Guodong Guo , Xin Chen , Haijian Huang","doi":"10.1016/j.anndiagpath.2025.152481","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>Research on the expression of PD-L1 (clone SP263) in prostate cancer (PC) is rare. This study aims to investigate PD-L1 (SP263) expression and its clinicopathological correlations in PC.</div></div><div><h3>Methods</h3><div>A total of 265 PC samples at our center from 2021 to 2024 were included in this study. The clinical information and pathological data were collected. Whole-slide immunohistochemical analysis of PD-L1 (SP263), p53, ERG, PTEN, HER-2 and Ki67 was performed on PC samples, including core biopsies, radical prostatectomies, transurethral resections of the prostate and metastases. Next-generation sequencing was performed in 17 patients and the status of <em>TP53</em>, <em>BRCA1/2</em> were analyzed. Associations were assessed between PD-L1 status and clinicopathological parameters (age, preoperative serum prostate-specific antigen [PSA], surgical margin, Gleason Group [GG], TNM stage, Ki-67, p53/<em>TP53</em>, <em>BRCA1/2</em>, survival outcomes, etc.) using chi-square, Mann-Whitney U and Kaplan-Meier analyses.</div></div><div><h3>Results</h3><div>PD-L1 positivity (10.2 %, 27/265) correlated with advanced age (<em>P</em> = 0.007), high GG (<em>P</em> = 0.019), T3/4 stage (<em>P</em> = 0.001), positive surgical margin (<em>P</em> = 0.004), aberrant p53/TP53 (<em>P</em> = 0.043), and elevated Ki-67 (<em>P</em> = 0.042). No associations were observed between these factors (serum PSA, N category, M category, PTEN, ERG, BRCA1/2, or survival outcomes) and PD - L1.</div></div><div><h3>Conclusion</h3><div>The expression of PD-L1 (SP263) is positively associated with pathologically aggressive parameters in PC. This finding implies the potential value of PD-L1 as a biomarker for risk stratification. Moreover, it indicates the possibility of using PD-L1 (SP263) and p53 expression to guide the combinational application of mutated p53 inhibitors and PD-1/PD-L1 antibodies in PC.</div></div>","PeriodicalId":50768,"journal":{"name":"Annals of Diagnostic Pathology","volume":"78 ","pages":"Article 152481"},"PeriodicalIF":1.5000,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"PD - L1 (SP263) expression correlates with pathological aggressive parameters in prostate cancer\",\"authors\":\"Xiaopeng Zhuang , Huiting Li , Zhijie You , Hui Cheng , Guodong Guo , Xin Chen , Haijian Huang\",\"doi\":\"10.1016/j.anndiagpath.2025.152481\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><div>Research on the expression of PD-L1 (clone SP263) in prostate cancer (PC) is rare. This study aims to investigate PD-L1 (SP263) expression and its clinicopathological correlations in PC.</div></div><div><h3>Methods</h3><div>A total of 265 PC samples at our center from 2021 to 2024 were included in this study. The clinical information and pathological data were collected. Whole-slide immunohistochemical analysis of PD-L1 (SP263), p53, ERG, PTEN, HER-2 and Ki67 was performed on PC samples, including core biopsies, radical prostatectomies, transurethral resections of the prostate and metastases. Next-generation sequencing was performed in 17 patients and the status of <em>TP53</em>, <em>BRCA1/2</em> were analyzed. Associations were assessed between PD-L1 status and clinicopathological parameters (age, preoperative serum prostate-specific antigen [PSA], surgical margin, Gleason Group [GG], TNM stage, Ki-67, p53/<em>TP53</em>, <em>BRCA1/2</em>, survival outcomes, etc.) using chi-square, Mann-Whitney U and Kaplan-Meier analyses.</div></div><div><h3>Results</h3><div>PD-L1 positivity (10.2 %, 27/265) correlated with advanced age (<em>P</em> = 0.007), high GG (<em>P</em> = 0.019), T3/4 stage (<em>P</em> = 0.001), positive surgical margin (<em>P</em> = 0.004), aberrant p53/TP53 (<em>P</em> = 0.043), and elevated Ki-67 (<em>P</em> = 0.042). No associations were observed between these factors (serum PSA, N category, M category, PTEN, ERG, BRCA1/2, or survival outcomes) and PD - L1.</div></div><div><h3>Conclusion</h3><div>The expression of PD-L1 (SP263) is positively associated with pathologically aggressive parameters in PC. This finding implies the potential value of PD-L1 as a biomarker for risk stratification. Moreover, it indicates the possibility of using PD-L1 (SP263) and p53 expression to guide the combinational application of mutated p53 inhibitors and PD-1/PD-L1 antibodies in PC.</div></div>\",\"PeriodicalId\":50768,\"journal\":{\"name\":\"Annals of Diagnostic Pathology\",\"volume\":\"78 \",\"pages\":\"Article 152481\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2025-04-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Diagnostic Pathology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1092913425000462\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PATHOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Diagnostic Pathology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1092913425000462","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

目的研究PD-L1（克隆SP263）在前列腺癌（PC）中的表达情况。本研究旨在探讨PD-L1 （SP263）在PC中的表达及其临床病理相关性。方法选取本中心2021 - 2024年共265份PC样本进行研究。收集临床资料和病理资料。对PC标本进行PD-L1 （SP263）、p53、ERG、PTEN、HER-2和Ki67的全片免疫组化分析，包括核心活检、根治性前列腺切除术、经尿道前列腺切除术和转移灶。对17例患者进行新一代测序，分析TP53、BRCA1/2的状态。采用卡方分析、Mann-Whitney U和Kaplan-Meier分析评估PD-L1状态与临床病理参数（年龄、术前血清前列腺特异性抗原（PSA）、手术切缘、Gleason Group [GG]、TNM分期、Ki-67、p53/TP53、BRCA1/2、生存结局等）之间的关系。结果pd - l1阳性（10.2%,27/265）与高龄（P = 0.007）、高GG （P = 0.019）、T3/4分期（P = 0.001）、手术切缘阳性（P = 0.004）、p53/TP53异常（P = 0.043）、Ki-67升高（P = 0.042）相关。这些因素（血清PSA、N类、M类、PTEN、ERG、BRCA1/2或生存结果）与PD - L1之间未观察到关联。结论PD-L1 （SP263）的表达与PC的病理侵袭参数呈正相关。这一发现暗示了PD-L1作为风险分层生物标志物的潜在价值。此外，该研究还提示了利用PD-L1 （SP263）和p53表达来指导突变p53抑制剂和PD-1/PD-L1抗体在PC中联合应用的可能性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

PD - L1 (SP263) expression correlates with pathological aggressive parameters in prostate cancer

Objective

Research on the expression of PD-L1 (clone SP263) in prostate cancer (PC) is rare. This study aims to investigate PD-L1 (SP263) expression and its clinicopathological correlations in PC.

Methods

A total of 265 PC samples at our center from 2021 to 2024 were included in this study. The clinical information and pathological data were collected. Whole-slide immunohistochemical analysis of PD-L1 (SP263), p53, ERG, PTEN, HER-2 and Ki67 was performed on PC samples, including core biopsies, radical prostatectomies, transurethral resections of the prostate and metastases. Next-generation sequencing was performed in 17 patients and the status of TP53, BRCA1/2 were analyzed. Associations were assessed between PD-L1 status and clinicopathological parameters (age, preoperative serum prostate-specific antigen [PSA], surgical margin, Gleason Group [GG], TNM stage, Ki-67, p53/TP53, BRCA1/2, survival outcomes, etc.) using chi-square, Mann-Whitney U and Kaplan-Meier analyses.

Results

PD-L1 positivity (10.2 %, 27/265) correlated with advanced age (P = 0.007), high GG (P = 0.019), T3/4 stage (P = 0.001), positive surgical margin (P = 0.004), aberrant p53/TP53 (P = 0.043), and elevated Ki-67 (P = 0.042). No associations were observed between these factors (serum PSA, N category, M category, PTEN, ERG, BRCA1/2, or survival outcomes) and PD - L1.

Conclusion

The expression of PD-L1 (SP263) is positively associated with pathologically aggressive parameters in PC. This finding implies the potential value of PD-L1 as a biomarker for risk stratification. Moreover, it indicates the possibility of using PD-L1 (SP263) and p53 expression to guide the combinational application of mutated p53 inhibitors and PD-1/PD-L1 antibodies in PC.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Annals of Diagnostic Pathology 医学-病理学

CiteScore

3.90

自引率

5.00%

发文量

149

审稿时长

26 days

期刊介绍： A peer-reviewed journal devoted to the publication of articles dealing with traditional morphologic studies using standard diagnostic techniques and stressing clinicopathological correlations and scientific observation of relevance to the daily practice of pathology. Special features include pathologic-radiologic correlations and pathologic-cytologic correlations.